Independent component analysis and decision trees for ECG holter recording de-noising.
Ontology highlight
ABSTRACT:
SUBMITTER: Kuzilek J
PROVIDER: S-EPMC4048160 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
Publications
Independent component analysis and decision trees for ECG holter recording de-noising.
Kuzilek Jakub J Kremen Vaclav V Soucek Filip F Lhotska Lenka L
PloS one 20140606 6
We have developed a method focusing on ECG signal de-noising using Independent component analysis (ICA). This approach combines JADE source separation and binary decision tree for identification and subsequent ECG noise removal. In order to to test the efficiency of this method comparison to standard filtering a wavelet- based de-noising method was used. Freely data available at Physionet medical data storage were evaluated. Evaluation criteria was root mean square error (RMSE) between original ...[more]
Similar Datasets
Project description:ObjectiveIdentification of ischemic stroke patients at high risk for paroxysmal atrial fibrillation (pAF) during 72 hours Holter ECG might be useful to individualize the allocation of prolonged ECG monitoring times, currently not routinely applied in clinical practice.MethodsIn a prospective multicenter study, the first analysable hour of raw ECG data from prolonged 72 hours Holter ECG monitoring in 1031 patients with acute ischemic stroke/TIA presenting in sinus rhythm was classified by an automated software (AA) into "no risk of AF" or "risk of AF" and compared to clinical variables to predict AF during 72 hours Holter-ECG.ResultspAF was diagnosed in 54 patients (5.2%; mean age: 78 years; female 56%) and was more frequently detected after 72 hours in patients classified by AA as "risk of AF" (n = 21, 17.8%) compared to "no risk of AF" (n = 33, 3.6%). AA-based risk stratification as "risk of AF" remained in the prediction model for pAF detection during 72 hours Holter ECG (OR3.814, 95% CI 2.024-7.816, P < 0.001), in addition to age (OR1.052, 95% CI 1.021-1.084, P = 0.001), NIHSS (OR 1.087, 95% CI 1.023-1.154, P = 0.007) and prior treatment with thrombolysis (OR2.639, 95% CI 1.313-5.306, P = 0.006). Similarly, risk stratification by AA significantly increased the area under the receiver operating characteristic curve (AUC) for prediction of pAF detection compared to a purely clinical risk score (AS5F alone: AUC 0.751; 95% CI 0.724-0.778; AUC for the combination: 0.789, 95% CI 0.763-0.814; difference between the AUC P = 0.022).InterpretationAutomated software-based ECG risk stratification selects patients with high risk of AF during 72 hours Holter ECG and adds predictive value to common clinical risk factors for AF prediction.
| S-EPMC7545589 | biostudies-literature
Project description:Understanding complex networks of protein-protein interactions (PPIs) is one of the foremost challenges of the post-genomic era. Due to the recent advances in experimental bio-technology, including yeast-2-hybrid (Y2H), tandem affinity purification (TAP) and other high-throughput methods for protein-protein interaction (PPI) detection, huge amounts of PPI network data are becoming available. Of major concern, however, are the levels of noise and incompleteness. For example, for Y2H screens, it is thought that the false positive rate could be as high as 64%, and the false negative rate may range from 43% to 71%. TAP experiments are believed to have comparable levels of noise.We present a novel technique to assess the confidence levels of interactions in PPI networks obtained from experimental studies. We use it for predicting new interactions and thus for guiding future biological experiments. This technique is the first to utilize currently the best fitting network model for PPI networks, geometric graphs. Our approach achieves specificity of 85% and sensitivity of 90%. We use it to assign confidence scores to physical protein-protein interactions in the human PPI network downloaded from BioGRID. Using our approach, we predict 251 interactions in the human PPI network, a statistically significant fraction of which correspond to protein pairs sharing common GO terms. Moreover, we validate a statistically significant portion of our predicted interactions in the HPRD database and the newer release of BioGRID. The data and Matlab code implementing the methods are freely available from the web site: http://www.kuchaev.com/Denoising.
| S-EPMC2711306 | biostudies-literature
Project description:BACKGROUND: This paper compares the most common digital signal processing methods of exon prediction in eukaryotes, and also proposes a technique for noise suppression in exon prediction. The specimen used here which has relevance in medical research, has been taken from the public genomic database - GenBank. METHODS: Here exon prediction has been done using the digital signal processing methods viz. binary method, EIIP (electron-ion interaction psuedopotential) method and filter methods. Under filter method two filter designs, and two approaches using these two designs have been tried. The discrete wavelet transform has been used for de-noising of the exon plots. RESULTS: Results of exon prediction based on the methods mentioned above, which give values closest to the ones found in the NCBI database are given here. The exon plot de-noised using discrete wavelet transform is also given. CONCLUSION: Alterations to the proven methods as done by the authors, improves performance of exon prediction algorithms. Also it has been proven that the discrete wavelet transform is an effective tool for de-noising which can be used with exon prediction algorithms.
| S-EPMC3009523 | biostudies-literature
Project description:Background:Patients with chronic obstructive pulmonary disease (COPD) are at risk of developing cardiac arrhythmias and elevated heart rate. A theoretical mechanistic association based on the interaction of long-acting ?2-agonists (LABAs) with adrenoreceptors in the heart and vasculature is assumed as a potential class-related risk. Therefore, we performed a pooled analysis of Holter electrocardiogram (ECG) data from four 48-week, randomized, double-blind, placebo-controlled, parallel-group, Phase III clinical trials evaluating olodaterol (5 ?g or 10 ?g) or formoterol (12 µg) versus placebo. Methods:We analyzed Holter ECG data from a representative subset of 775 patients with Global Initiative for Chronic Obstructive Lung Disease stage 2-4 COPD from four studies (1222.11-14) assessing olodaterol (5 ?g and 10 ?g) and formoterol (12 µg) versus placebo. Results:No statistically significant (P>0.3) or clinically relevant differences in the shift from baseline of premature supraventricular or ventricular beats were observed among the active treatment and the placebo groups. Minor and transient differences were observed in the adjusted mean heart rate from baseline during treatment in all groups. There was a numerically small but statistically significant increase for formoterol at Week 24, olodaterol 5 ?g at Weeks 12 and 40, and olodaterol 10 ?g at Week 40 (all less than 3.0 beats per minute). Mean heart rates returned to a statistically non-significant change at Week 48 for all treatment groups. No increase in major adverse cardiovascular events was observed. Conclusion:Treatment with olodaterol or formoterol is not associated with arrhythmias or a persistent increase in heart rate as assessed by Holter ECG in patients with COPD. Trial Registration:ClinicalTrials.gov identifiers: NCT00782210 (1222.11); NCT00782509 (1222.12); NCT00793624 (1222.13); NCT00796653 (1222.14).
| S-EPMC7428408 | biostudies-literature
Project description:PurposeTo compare daily ECG transmissions using trans-telephonic monitoring (TTM) with repeated 6-day Holter ECG in detecting atrial fibrillation (AF) episodes following ablation.MethodsEach patient underwent two types of recordings: daily ECG TTM lasting 30 s and standard 6-day ambulatory ECG monitoring performed 3, 6, and 12 months after ablation. Number of patients with detected AF recurrences, time to first detected recurrence of AF, and AF burden were assessed.ResultsFifty patients (9 females, mean age 57 ± 11 years) were included. The mean duration of the follow-up was 382 ± 38 days. A total of 17,573 (mean 351 ± 111 per patient) TTM recordings were performed and 99.95% of recordings were of quality sufficient to assess cardiac rhythm. Altogether, 14 (28%) patients had AF recurrence. Holter ECG detected AF recurrence in 7 (14%) patients whereas TTM - in 12 (24%) patients, p = 0.0416 (TTM only - 7 (14%), Holter ECG only - 2 (4%), and both methods - 5 (10%)). Time to the first AF recurrence tended to be shorter using TTM than Holter ECG (156 ± 91 vs 204 ± 121 days, p = 0.0819). There was no significant difference in AF burden assessed by TTM versus Holter ECG recordings 3.1 ± 0.14% vs 4.8 ± 0.2%, p = 0.21.ConclusionsCompared with Holter ECG, daily 30-s ECG recordings detected more patients with AF recurrences. Time to first detected AF episode tended to be shorter using TTM. Daily ECG recordings transmitted using smartphone may replace standard Holter ECG in detecting AF after ablation.Trial registrationClinical Trials Identifier: NCT03877913.
| S-EPMC8894837 | biostudies-literature
Project description:BackgroundThe development of wearable health monitoring systems is garnering tremendous interest in research, technology and commercial applications. Their ability of providing unique capabilities in continuous, real-time, and non-invasive tracking of the physiological markers of users can provide insights into the performance and health of individuals. Electrocardiogram (ECG) signals are of particular interest, as cardiovascular disease is the leading cause of death globally. Monitoring heart health and its conditions such as ventricular disturbances and arrhythmias can be achieved through evaluating various features of ECG such as R-peaks, QRS complex, T-wave, and P-wave. Despite recent advances in biosensors for wearable applications, most of the currently available solutions rely solely on a single system attached to the body, limiting the ability to obtain reliable and multi-location biosignals. However, in engineering systems, sensor fusion, which is the optimal integration and processing of data from multiple sensors, has been a common theme and should be considered for wearables. In recent years, due to an increase in the availability and variety of different types of sensors, the possibility of achieving sensor fusion in wearable systems has become more attainable. Sensor fusion in multi-sensing systems results in significant enhancements of information inferences compared to those from systems with a sole sensor. One step towards the development of sensor fusion for wearable health monitoring systems is the accessibility to multiple reliable electrophysiological signals, which can be recorded continuously.ResultsIn this paper, we develop a textile-based multichannel ECG band that has the ability to measure ECG from multiple locations on the waist. As a proof of concept, we demonstrate that ECG signals can be reliably obtained from different locations on the waist where the shape of the QRS complex is nearly comparable with recordings from the chest using traditional gel electrodes. In addition, we develop a probabilistic approach-based on prediction and update strategies-to detect R-peaks from noisy textile data in different statuses, including sitting, standing, and jogging. In this approach, an optimal search method is utilized to detect R-peaks based on the history of the intervals between previously detected R-peaks. We show that the performance of our probabilistic approach in R-peak detection is significantly better than that based on Pan-Tompkins and optimal-threshold methods.ConclusionA textile-based multichannel ECG band was developed to track the heart rate changes from multiple locations on the waist. We demonstrated that (i) the ECG signal can be detected from different locations on the waist, and (ii) the accuracy of the detected R-peaks from textile sensors was improved by using our proposed probabilistic approach. Despite the limitations of the textile sensors that might compromise the quality of ECG signals, we anticipate that the textile-based multichannel ECG band can be considered as an effective wearable system to facilitate the development of sensor fusion methodology for pervasive and non-invasive health monitoring through continuous tracking of heart rate variability (HRV) from the waist. In addition, from the commercialization point of view, we anticipate that the developed band has the potential to be integrated into garments such as underwear, bras or pants so that individuals can use it on a daily basis.
| S-EPMC7296680 | biostudies-literature
Project description:IntroductionThe resting ECG is the most commonly used tool to assess cardiac electrophysiology. Previous studies have estimated heritability of ECG parameters based on these snapshots of the cardiac electrical activity. In this study we set out to determine whether analysis of heart rate specific data from Holter ECGs allows more complete assessment of the heritability of ECG parameters.Methods and resultsHolter ECGs were recorded from 221 twin pairs and analyzed using a multi-parameter beat binning approach. Heart rate dependent estimates of heritability for QRS duration, QT interval, Tpeak-Tend and Theight were calculated using structural equation modeling. QRS duration is largely determined by environmental factors whereas repolarization is primarily genetically determined. Heritability estimates of both QT interval and Theight were significantly higher when measured from Holter compared to resting ECGs and the heritability estimate of each was heart rate dependent. Analysis of the genetic contribution to correlation between repolarization parameters demonstrated that covariance of individual ECG parameters at different heart rates overlap but at each specific heart rate there was relatively little overlap in the genetic determinants of the different repolarization parameters.ConclusionsHere we present the first study of heritability of repolarization parameters measured from Holter ECGs. Our data demonstrate that higher heritability can be estimated from the Holter than the resting ECG and reveals rate dependence in the genetic-environmental determinants of the ECG that has not previously been tractable. Future applications include deeper dissection of the ECG of participants with inherited cardiac electrical disease.
| S-EPMC4850154 | biostudies-literature
Project description:In clinical trials, traditionally only a limited number of 12-lead resting electrocardiograms (ECGs) can be recorded and, thus, long intervals may elapse between assessment timepoints and valuable information may be missed during times when patients' cardiac electrical activity is not being monitored. These limitations have led to the increasing use of Holter recorders which provide continuous data registrations while reducing the burden on patients and freeing up time for clinical trial staff to perform other tasks. However, there is a shortage of data comparing the two approaches. In this study, data from a randomized, double-blind, four-period, crossover thorough QT study in 40 healthy subjects were used to compare continuous 12-lead Holter recordings to standard 12-lead resting ECGs which were recorded in parallel. Heart rate and QT interval data were estimated by averaging three consecutive heartbeats. Values exceeding the sample average by more than 5% were tagged as outliers and excluded from the analysis. Visual comparisons of the ECG waveforms of the Holter signal showed a good correlation with resting ECGs at matching timepoints. Resting ECG data revealed sex differences that Holter data did not show. Specifically, women were found to have a longer QTcF of 20 ms, while men had a lower heart rate. We found that continuous recordings provided a more accurate reflection of changes in cardiac electrical activity over 24 hr. However, manual adjudication is still required to ensure the quality and accuracy of ECG data, and that only artifacts are removed thereby avoiding loss of true signals.
| S-EPMC8411681 | biostudies-literature
Project description:This paper presents a wearable electrophysiological interface with enhanced immunity to motion artifacts. Anti-artifact schemes, including a patch-type modular structure and real-time automatic level adjustment, are proposed and verified in two wireless system prototypes of a patch-type electrocardiogram (ECG) module and an electromyogram (EMG)-based robot-hand controller. Their common ExG readout integrated circuit (ROIC), which is reconfigurable for multiple physiological interfaces, is designed and fabricated in a 0.18 μm CMOS process. Moreover, analog pre-processing structures based on envelope detection are integrated with one another to mitigate signal processing burdens in the digital domain effectively.
| S-EPMC5579532 | biostudies-literature
Project description:Tiotropium is generally well tolerated; however, there has been debate whether antimuscarinics, particularly tiotropium administered via Respimat(®) Soft Mist(™) Inhaler, may induce cardiac arrhythmias in a vulnerable subpopulation with cardiovascular comorbidity. The aim of this study was to provide evidence of the cardiac safety of tiotropium maintenance therapy.Combined analysis of Holter electrocardiogram (ECG) data from clinical trials of tiotropium in chronic obstructive pulmonary disease (COPD). Trials in the Boehringer Ingelheim clinical trials database conducted between 2003 and 2012, involving tiotropium HandiHaler(®) 18 ?g and/or tiotropium Respimat(®) (1.25-, 2.5-, 5.0- and 10-?g doses) were reviewed. All trials involving Holter-ECG monitoring during this period were included in the analysis. Men and women aged ? 40 years with a smoking history of ? 10 pack-years, and a clinical diagnosis of COPD were included. Holter ECGs were evaluated for heart rate (HR), supraventricular premature beats (SVPBs), ventricular premature beats (VPBs) and pauses. Quantitative and categorical end-points were derived for each of the Holter monitoring days.Four trials (n = 727) were included in the analysis. Respimat(®) (1.25-10 ?g) or HandiHaler(®) (18 ?g) was not associated with changes in HR, SVPBs, VPBs and pauses compared with placebo or the pretreatment baseline period. In terms of cardiac arrhythmia end-points, there was no evidence for an exposure-effect relationship.In this analysis, tiotropium maintenance therapy administered using Respimat(®) (1.25-10 ?g) or HandiHaler(®) (18 ?g) once daily for periods of up to 48 weeks was well tolerated with no increased risk of cardiac arrhythmia in patients with COPD.
| S-EPMC4383643 | biostudies-literature